Search

Displaying results 1391 - 1400 of 6835 in total
  1. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. … [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816]

  2. Drug

    Ferumoxytol

    go.drugbank.com/drugs/DB06215
    ApprovedInvestigational

    In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns. … high dose by rapid intravenous injection [L2181].

  3. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … is amenable to exon 51 skipping.

  4. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. … These drugs are effective in patients who are intolerant or resistant to [DB01200].

  5. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [T177] The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide bridges.

  6. Drug

    Camphor

    go.drugbank.com/drugs/DB01744
    ApprovedInvestigationalWithdrawn

    The FDA ruled that camphorated oil could not be marketed in the United States and that no product could contain a concentration higher than 11%.

    Mixtures: Zam-Buk Ointment, CHAP ICE (R) MEDICATED
  7. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying … [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production.

  8. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    [A249070] It is a taurine conjugate of [ursodeoxycholic acid] [A249065] with comparable therapeutic efficacy and safety,[A249070] but a much higher hydrophilicity. … [A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative.

  9. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones … The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use

  10. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted … Panobinostat is marketed by Novartis under the brand name Farydak.